Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16856519 | 0.76 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL18185195 | 0.75 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL16837149 | 0.69 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL16856510 | 0.69 | HCRTR1 (0.64) | HCRTR1HCRTR2PSMB1 | |
| SCHEMBL16837153 | 0.69 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL16837152 | 0.69 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL16856640 | 0.69 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL16837140 | 0.67 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15758617 | 0.66 | HCRTR1 (0.46) | HCRTR1HCRTR2IRAK4CHEK1KCNH2 | |
| SCHEMBL16843052 | 0.65 | HCRTR2 (0.48) | HCRTR1HCRTR2IRAK4CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556190-B2 | Piperidinyloxy lactone orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556190-B2 | Piperidinyloxy lactone orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556190-B2 | Piperidinyloxy lactone orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095442-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885PSMB1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.